preview august
nbi btk outperform
respect month grew time
nbi saw btk biotech trade five-year price-to-earnings
low see upsid sector base upon favor regulatori
environ data catalyst evolv technolog platform look
forward despit upsid weve seen biotech indic remain bullish
biotech sector reiter buy adap arri argx
btk break new high btk broke new high juli nbi
approach all-tim high juli high driven strong
ytd perform mid-cap nudg higher revers
larg cap perform also near all-tim
high current januari high
solid earn despit suppress price earn
solid larg cap biotech pharma despit trump rhetor larg
part suppress price increas dr gawand thought
write healthcar ineffici decad
month name ceo buffett/bezos/dimon healthcar ventur
catalyst look encourag continu out-performance
continu posit outlook balanc earn see
team earn preview solid set data catalyst
page report catalyst list biotech
continu trade five-year price-to-earnings low near term would focu
three catalyst
expand coverag total biotech stock coverag launch
coverag three biotech name juli buy rate deciphera
make great
expand coverag oncolog nash top read note
month juli also found page
catalyst across coverag ttph pdufa date
eravacyclin august pivot orr data phase
unity-cl trial possibl acceler approv sale
data cabozantinib follow seri io combo data next
strh biotech monthli preview
exhibit start page pleas email us
excel version
catalyst list exhibit
full catalyst list cover compani
list exhibit
exhibit btk nbi outperform month year
suntrust robinson humphrey research factset price updat close juli
exhibit top bottom smid cap perform juli
suntrust robinson humphrey research factset stock price updat close juli
page
cap cap cap ytd btk nbi outperform julybtknbi return btk nbi biotechnolog
suntrust robinson humphrey research bloomberg updat close juli
care saw net cash outflow juli trend stabil btk ytd nbi ytd
outperform broader market ytd see exhibit fund outflow sinc begin
broader healthcar etf like xlv ibb pharma healthcar provid servic tool equip ishar nasdaq biotechnolog
etf ibb pharmaceut etf ihe see exhibit given strong fundament posit high-profil data seen
expect see net inflow biotech
pleas contact strh salesperson strh event
page
suntrust robinson humphrey research factset stock price updat close juli
page
pleas see exhibit detail
page
exhibit catalyst strh biotech coverag univers page
page
tickerassettimingcatalyststrh patient enrol phase i/ii studi mp awe expect complet patient enrol phase i/ii studi fda ema regard pivot trial design mp awe believ cognit function improv one primari end-point mp phase studi rdebw anticip posit data phase studi given robust result phase i/ii phase efficaci data solid tumor includ nsclc melanoma head neck expect manag advers effect orr dose expans r/r hl dataw expect efficaci remain histor keytruda data patient month follow lymphomaw expect updat phsa enrol phase claridhi trial previous treat advanc cholangiocarcinomapivot data like late registration-en phase combo w/ trial patient fit approv could provi upsid submiss ema r/r amlswift eu uptak could provid upsid plazomicin cuti emaw expect approv opportun singl pivot phase studi cutith fda agre one singl studi suffici support approv data data phase treatment-nav adolesc adult ahu studi approv expect becom new soc phase prevent trial relaps nmosdwhil model believ success indic could add phase trial gmg proof-of-conept studi immunoglobulin nephropathi igan addit indic could provid upsid placebo-control phase ii trial palmoplantar pustular psoriasi ppp expect top-line data data phase iia trial sever adult eosinophil asthmaw expect posit result base upon genet linkag sever eosinophil data phase ii trial gener psutular psoriasisposit data could increas investor interest second assett phase ii poc data itp ashan increas platelet could drive upsid itp data itpan increas platelet could drive upsid phase i/ii aml data ashw believ target could repres best-in-class approach amlmediumsunejaarrybini opdivo /- mss dataw expect intial sign phase ii enrol propgress supranuclear palsi psp psp could addit tauopathi target beyond alzheim submiss rrmscould provid addit oral ms prospect studi extend dose intervalssuccess studi could provid extend dose interv tysabri potenti reduc risk pml give addit flexibl prescribinglowsuneja biotechnolog
exhibit catalyst strh biotech coverag univers page
page
tickerassettimingcatalyststrh eu data expect month trm grade acut gvhd chronic gvhd pancreat cancer dataw expect valid bellicum go switch technolog initi sign aml md dataw expect initi sign efficacylowlawsonbluelentiglobindec studi patient tdt genotyp ashw believ genotyp difficult treat highnashbluelentiglobindec studi patient scd ashw believ focu durabilityhighnashbluelentiglobindec studi patient tdt non- genotyp ashdur data studi patient r/r multipl myeloma ashw see whether better on-going starbeam clinic studi patient caldw believ data limit impact stock due small patient phase enrollmentth studi one-year durat top-lin data expect data phase i/ii studi hemophilia ainvestor focu whether fv activ sustain data phase ii studi seladelpar patient pbcwe expect compani continu report posit phase studi pbcthe trial may take full year enrol top-lin data expect submiss myelofibrosisaddit approv need offest futur declin revlimid revenuemediumsunejacelgrevlimidsummer/earli fall expert wit testimoni on-going litig dr reddi soverhang stock like remain litiat dr reddi phase robust trial activ b-cell subtyp dlbclrevlimid approv could offer addit option treat updat dataupd efficaci safeti data larger updat dataupd efficaci safeti data larger eu chmp opinion ocarian cacner expect posit opinionlowlawsonclvsrucapariboct cancer germlin somat brca/atm/brca-lik mutat mcrpc relaps taxan ar therapi expect interim phase data patient enrol phase trial challeng recruit action date lambert-eaton myasthen syndromew expect result studyour kol consult highli posit firdaps efficaci phase data solid tumor lymphomasw expect first object respons oral inhibitor european trial beta-thalassemiaw expect color around time data readoutshighlawson biotechnolog
exhibit catalyst strh biotech coverag univers page
page
tickerassettimingcatalyststrh clincal data basket melanomaw expect see updat clinic clincal data basket melanomaw expect see initi clinic data part aml like ashw expect see updat initi phase data like sitcw expect see updat initi phase data data primari hyperoxaluria phi phii expect see initi efficaci data ph file dcr-hbv chronic hepat patientsth anim data demonstr date file undisclos candid second rare diseasew believ furthur valid dicerna technolog platform programl phase dataw expect initi sign clinic phase ii registr data solid tumor epithelioid sarcoma expect orr phase ii data wild type folicular lymphomaw expect updat data present medic phase ii studi cystic fibrosisw expect initi phase ii trial nephrepath cystinosisw expect initi timelownashexelcabozantinib data bladder cancer advanc rccwe expect phase datahighlawsonexelcabozantinib opdivo data hccwe expect earli phase safeti efficaci updat potenti acceler approvalacceler approv could add upsid part data like ashful data may provid insight potenti acceler studi design nashth fda feedback phase studi design inform assess success rate pivot phase trial r/r amlw believ os appropri primari endpoint offer complet measur benefit consortium-fund trial frontlin amlw anticip benefit frontlin aml base phase ii phase data scd patientswhil model posit readout could add increment upsidemediumsunejaincyjakafisept dermat dataw expect data topic applic jakafi bladder cancer dataw expect addit phase data phase iib shine trial hswe expect see improv hiscr line better roll nda submiss lumateperon schizophreniaw expect fda approv lumateperon current data data phase i/ii mild moder parkinson diseasew includ indic compani data studi phase monotherapi studi bipolar depressionposit data like strong catalyst interim analysi phase agit associ dementia includ alzheim diseasew anticip posit interim data support anoth indic expansionhighnashljpcgiaprezaaug decisionmtap approv could acceler uptak phase ii program -thalassemia hereditari hemochromatosisw expect investor focu begin shift second asset advanc readout ema decis giaprezaeu approv could provid upsid modelmediumsuneja biotechnolog
exhibit catalyst strh biotech coverag univers page
page
tickerassettimingcatalyststrh phase ib data monotherapi combo w/rituxan like potenti best class efficaci single-arm global registr studi r/r flpotenti best class efficaci flmediumsunejamgnxenoblituzumab combo data solid tumorsw expect initi sign addit phase ii opdivo combo dataw expect orr approxim filingw expect accept file coupl prioriti review filingw expect accept file coupl prioriti review earningsstrateg updatew expect nlnk annouc program pursu indoximodmediumlawsonnlnkindoximod dataw expect updat aml updat phase i/ii studi hemophilia agiven less optimin data present data updat critial ema action luxturna retin dystrophyw expect ema approv given posit data pivot updat phase i/ii studi choroideremiaa long term follow-up period suggest magnitud separ treat untreat eye small first year otiprio assetw believ success divestitur help otic maintain healthi balanc data dose-confirm studi look mean level week decis market author mp viiw expect approv base larg posit phase data phase ii studi tiow expect posit result base posit fda possibl earli file base current phase ii dataw cautiosli optimist fda phase studi lc-faodth phase ii data show reduct mean annual rate phase studi ds movement disorderw expect data phase movement disord studi patient ds data second cohort phase i/ii studi over-the-counter deficiencyw expect posit efficaci result base initi data first phase i/ii cohort gsdiaw expect posit efficaci signal first ii data gmgin view soliri approv gmg provid regulatori pathway submiss base odyssey outcom datacompetitor repatha shown uptick sale view label updat praluent combin price drop could help regulatori decis moderate-to-sever asthmawhil continu expect approv indic liberti asthma quest result mix could repres limit readout nasal polypswhil immedi focu investor success nasal polyp could critic achiev investor high expect action date moder sever expect data pivot trial previous phase ii patient expect posit data base posit read-through studi data phase mad studi healthi volunteersth nmda program expand phase studi mddpivot trial mdd also support scientif advic brexanolon iv expect posit opinionmediumnash biotechnolog
exhibit catalyst strh biotech coverag univers page
page
tickerassettimingcatalyststrh data phase trial frontlin mtcldespit lower expect event rate manag indic readout remain track phase ii data post-cpi/platinum local advanc muc cohortev track becom soc phase studi cdiw expect posit outcom phase studi given superior demonstr phase ii phase studi therapi collabor myonexu expand neuromuscular signal dose first ppmo programw expect posit data first ppmo submiss ppmo exon program candid potenti expand patient popul cover dmd patient amen exon submiss acceler approv golodirsenw expect time nda submiss fda accept data phase studi data readout collabor program phase cohort expans data monotherapi trialpreliminari efficaci data orr data phase unity-cl trial would support acceler approvalstrong pivot data could lead acceler approv cll indic worth regulatori file high-risk r/r cll base genuinew believ unity-cl data key driver management decis file enrol phase trial rmswe believ updat phase ii rm data continu show favor profil bode well pivot readout like mono combo data nsclcwe expect greater monthshighlawsontsrozejula cancer dataw expect matur data date iv eravacyclin ciaiw expect approv opportun peak phase mad studi antibiot candid treatment respiratori infect caus bacteri phase mad studi antibiot candid highli activ mdr multipl myelomaw expect see initi phase data r/r multipl b-cell nhlwe expect see initi phase data b-cell nhlwe expect see better safety/efficaci ratio versu approv cell phase ii studi hypercholesterolemia nafld expect posit data base phase ib result readthrough safeti result phase ii studi patient recov hip fracturew expect encourag safeti result base posit phase ib studi gsd iaw expect posit data studi base vivo submiss x-aldw optimist base encourag preclin anim toxic data includ potenti ind nashw expect encourag data base preclin clinic initialt phase ii/ studi nashpend fda decis encourag base posit phase ib data eu-bas phase iia combo w/ lama laba copd maintenancefollow phase iia combo w/ lama laba result expect initi pivot trial copd phase studi dmdhighli encourag preclin data signific unmet need dmdhighnash biotechnolog
exhibit short interest float strh biotech coverag
chang short interest june juli
coverag univers akao short stock akao believ investor
continu think achaogen face strong headwind commerci roll zemdri plazomicin given
zemdri limit label black box warn believ high si may relat slow clinic
progress mp iiia mp iiib rdeb program well lack licens like driven
investor concern giapreza overal commerci opportun launch trajectori
page
exhibit short interest float broader biotech space top
chang short interest june juli
page
exhibit biotech sector trade discount averag
suntrust robinson humphrey research factset stock price updat close juli
trade discount pharma base forward price-to-earnings past decad biotech trade
averag premium pharma current biotech trade slight discount pharma
past six month longest biotech ever discount compar pharma data believ
highlight issu lag revenu growth point potenti solut
page
exhibit percent high strh biotech coverag
suntrust robinson humphrey research factset stock price updat close juli
qure high run ahead data sitravatinib post lung cancer
esmo week high improv prospect adcetri on-going launch chl strong pipelin
growth believ chang superior design pivot hemophilia studi posit could
page
tickercompani name rang high price ratinganalystanalystmrtxmirati lawsonsgenseattl sunejabmrnbiomarin nashrareultragenyx nashalxnalexion sunejaagioagio sunejaitciintra-cellular nashvktxvik nashljpcla jolla sunejaarryarray nashsagesag nashcllscellecti lawsononcespark sunejaregnregeneron nashbluebluebird nashsrptsarepta nashwvewav lawsonadapadaptimmun lawsonmeipmei nashcrspcrispr lawsonsrrasierra oncolog sunejacprxcatalyst lawsontgtxtg lawsongbtglob sunejararxra lawsoncelgcelgen sunejaabeo abeona sunejaglmdgalm nashvrnaverona sunejaincyincyt lawsoncyadcelyad lawsonblcmbellicum lawsonclvsclovi nashttphtetraphas lawsonnlnknewlink biotechnolog
exhibit percent high broader biotech space top
suntrust robinson humphrey research factset stock price updat close juli
exhibit percent broader biotech space bottom
suntrust robinson humphrey research factset stock price updat close juli
page
tickercompani name wk rang rang price ratinganalystnbixneurocrin bioscienc genet bioscienc name wk rang price ratinganalystnbrvnabriva prime oncolog oncolog
exhibit top read strh biotech note juli
page
tickertitleanalystpublish datelinkarri crsp mgnx catalyst preview arri crsp qure oncegen therapi hemophilia draft guidanc in-line announc trial compani notestrh earn preview chang strengthen regulatori submiss resign transit neg read uniqu kinas player upsid initi divest us right varubi increas focu navig come wave gene analysi show intrigu result price increas
compani mention note
page
strh biotech herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
yatin suneja herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
edward nash herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
